✦ LIBER ✦

HER-2/neu Oncogene Amplification in Stage I And Stage III Ovarian Papillary Serous Carcinoma

✍ Scribed by Alaa M Afify; Bruce A Werness; Hon Fong L Mark

Book ID: 112243912
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 272 KB
Volume: 66
Category: Article
ISSN: 0014-4800
DOI: 10.1006/exmp.1999.2255

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Her-2/neu expression and amplification i

Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms

✍ Yun Wu; Robert A. Soslow; David S. Marshall; Mario Leitao; Beiyun Chen 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Lack of prognostic implications of HER-2

Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the lung

✍ Giuseppe Pelosi; Barbara Del Curto; Patrizia Dell'Orto; Felice Pasini; Giulia Ve 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 306 KB

## Abstract HER‐2/__neu__ oncogene activation by either gene amplification and/or protein overexpression has been documented in several human malignancies. Irrespective of protein overexpression, HER‐2/__neu__ gene amplification is rare in lung cancer and studies on its prevalence and clinicopathol

Uterine papillary serous carcinoma: comp

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy

✍ Warner K Huh; Matthew Powell; Charles A Leath III; J.Michael Straughn Jr.; David 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 130 KB

HER-2/neu overexpression and amplificati

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription–polymerase chain reaction, and fluorescence in situ hybridization

✍ F.E ODICINO; E BIGNOTTI; E ROSSI; B PASINETTI; R.A TASSI; C DONZELLI; M FALCHETT 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB

Oncogenic PIK3CA gene mutations and HER2

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

✍ English, Diana P.; Bellone, Stefania; Cocco, Emiliano; Bortolomai, Ileana; Pecor 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 806 KB

Results of an Open-Label Study to Evalua

Results of an Open-Label Study to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Carboplatin-Containing Chemotherapy in Patients with Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Carcinoma (Stage I-IV) or Papillary Serous Cancer of the Uterus

✍ Patrick Timmins III; Daniel Kredentser; Kenneth Hancock; Mark Messing; Kristi A. 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 104 KB